The cumulative proportion of patients who had ever gained @ letters or more from baseline by month @ was @ % ( sham ) , @ % ( ranibizumab @ mg ) , and @ % ( ranibizumab @ mg ) in BRAVO and @ % , @ % , and @ % , respectively , in CRUISE .